Results 151 to 160 of about 17,592 (206)

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals. [PDF]

Cureus
Freitas R, Barroso T, Braga S, Santos CC, Batista M, Chaves A, Cabral S, Fortuna A, Patel V, Araújo J, Duarte T, Cabral TP, Silva S, Viana C, Baptista C, Gonçalves J, Dunões IQ, Eiriz I.   +17 more
europepmc   +1 more source

CRISPR activation screens identify oncogenic lncRNAs that are susceptible to CDK4/6 inhibitor treatment. [PDF]

Nat Commun
Wang Y, Zhao Y, Hu J, Wang Z, Pattarayan D, Li S, Zhang Y, Wang X, Wang Y, Xie W, Zhang M, Yang D.   +11 more
europepmc   +1 more source

Clinical features and management for CDK4/6 inhibitor-DILI. [PDF]

JHEP Rep
Riveiro-Barciela M, Esteban P, Vega-Cano KS, Mateos B, Miranda EL, Jara P, Martín M, Alonso López S, Salcedo M, Forns X, García-Fructuoso I, Martínez-Sáez O, Pinazo-Bandera J, García-Cortés M, Ribelles N, Romanos Nanclares Á, Morchón-Araujo D, Rodríguez CA, Lozano R, Domínguez-Gómez R, Cejuela M, Torres-Sempere J, Ruiz-Cobo JC, Villagrasa A, Zamora E, Buti M, Bellet M.   +26 more
europepmc   +1 more source

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma. [PDF]

ESMO Open
Babatunde OO, Seier K, Schwartz G, Keohan ML, D'Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, Tap WD, Dickson MA.   +14 more
europepmc   +1 more source

Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. [PDF]

Stat Med
Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.   +4 more
europepmc   +1 more source

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study. [PDF]

Breast
Ligorio F, Provenzano L, Fotia G, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Mazzoli G, Jacobs F, Armani G, Sposetti C, Zurlo C, Menichetti A, Griguolo G, Faso V, Boldrini L, Munzone E, Marra A, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, PALMARES-2 study group, Vernieri C.   +42 more
europepmc   +1 more source

An Extreme Clinical Diagnosis: Primary Metastatic Breast Cancer with Complete Bilateral Breast Contour Elimination and Ulceration. [PDF]

Diagnostics (Basel)
Zafrakas M, Argyriou T, Papasozomenou P, Emmanouilides C.   +3 more
europepmc   +1 more source

Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13. [PDF]

Front Immunol
Zhao Y, Zhao Y, Liu R, Li J, Wang Y.
europepmc   +1 more source

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study. [PDF]

Sci Rep
Oruç A, Deliktaş Onur İ, Uyar GC, Şahin TK, Tünbekici S, Arslan Kapuci A, Ulukal Karancı E, Kemik F, Yıldırım Dişli Ş, Ateş Ö, İnanç İmamoğlu G, Aksoy S, Çakar B, Özdemir N, Öztürk B, Selçukbiricik F, Koçak MZ, Karakurt Eryılmaz M, Araz M, Artaç M.   +19 more
europepmc   +1 more source

Post-Chemotherapy Antibody-Based Continuation and Maintenance Strategies in HER2-Positive Metastatic Breast Cancer: A Translational Narrative Review. [PDF]

Antibodies (Basel)
Pogoda K, Lewińska K, Kalman P, Bałata A, Wysocki PJ.   +4 more
europepmc   +1 more source